Back to today’s briefing

Story perspectives

Study Reveals Dalbavancin as Safer Staph Infection Treatment

8/14/2025

37 3

Summary

Story summary

A groundbreaking study from Duke Health reveals that dalbavancin, a two-dose antibiotic, matches the effectiveness of lengthy IV therapy for severe staph bloodstream infections. This innovative approach minimizes complications linked to PICC lines, providing a safer alternative for patients. Published in JAMA, these findings pave the way for expanded treatment options.

1 of 1

Story summary

A groundbreaking study from Duke Health reveals that dalbavancin, a two-dose antibiotic, matches the effectiveness of lengthy IV therapy for severe staph bloodstream infections. This innovative approach minimizes complications linked to PICC lines, providing a safer alternative for patients. Published in JAMA, these findings pave the way for expanded treatment options.